Long-term PPI use is associated with a modest increase in fracture risk — somewhere around 20–30% in relative terms for fractures overall, with the strongest signals in people who already have other risk factors for breaking a bone.
But here’s the finding that reframes the whole question, and that almost nobody writing about this mentions: when researchers measured actual bone density over ten years, PPI users didn’t lose bone any faster than non-users.
Fractures up, bone density unchanged. That combination tells you something important — whatever is going on, it probably isn’t PPIs thinning your skeleton.
Key Takeaways
- The original 2006 study found a 44% higher hip fracture risk after more than a year of PPI therapy, rising with duration and dose.
- A 10-year study measuring bone mineral density directly found no accelerated bone loss in PPI users.
- The Women’s Health Initiative, following 161,806 postmenopausal women, found no hip fracture association at all — only modest increases in spine, wrist and total fractures.
- Excess fracture risk appeared only in people who already had at least one other fracture risk factor.
- H2 blockers showed a similar fracture association, which is a strong hint that the pattern reflects who takes acid suppression rather than what the drugs do to bone.
- The COMPASS randomized trial found no significant difference in fractures over three years.
- Sensible response: if you’re postmenopausal or otherwise at risk of osteoporosis, get your bone health assessed on its own merits — and don’t let a PPI be the thing you never review.
Why anyone thought PPIs would weaken bone
The theory was reasonable. Calcium absorption — particularly from calcium carbonate, the form in most supplements — depends partly on stomach acid to dissolve it. Suppress the acid, absorb less calcium, and over years you’d expect thinner bones.
There was a second proposed route through magnesium. Long-term PPI use can cause low magnesium, and magnesium matters for parathyroid hormone regulation and bone metabolism.
Interestingly, there was also a theory pointing the other way. PPIs inhibit proton pumps, and osteoclasts — the cells that break bone down — use a vacuolar proton pump to do it. In principle these drugs might reduce bone breakdown.
So the mechanism was genuinely uncertain from the start. What settled the alarm was the epidemiology.
What the fracture studies found
The paper that started it analyzed UK general practice records: 13,556 hip fracture cases against 135,386 controls. More than a year of PPI therapy carried an adjusted odds ratio of 1.44. High-dose long-term use came in at 2.65. And the association strengthened steadily with duration — 1.22 at one year, 1.41 at two, 1.54 at three, 1.59 at four [Yang et al., JAMA, 2006].
That duration gradient looked convincing. Subsequent work complicated it.
A large US case-control study of 33,752 hip fracture cases found PPI use associated with fractures at an odds ratio of 1.30 — but with three findings that undercut a simple causal story. Risk fell away after stopping the drug. Higher daily dose mattered but increasing cumulative duration didn’t. And most tellingly, the excess risk appeared only in people who already had at least one other fracture risk factor. H2 blockers, meanwhile, showed a similar association at 1.18 [Corley et al., Gastroenterology, 2010].
That last detail deserves attention. H2 blockers work by a completely different route and cause far less acid suppression. If both drug classes show the same fracture pattern, the most economical explanation isn’t that two unrelated mechanisms happen to produce identical effects — it’s that people who take acid-suppressing drugs long-term differ from people who don’t.
The bone density paradox
Here’s the part I find most clarifying.
If PPIs cause fractures by weakening bone, then PPI users should lose bone density faster. That’s a testable prediction, and researchers tested it properly — 8,340 people in a Canadian population study, with bone density measured at the hip, femoral neck and lumbar spine at baseline, five years and ten years.
PPI users did have lower bone density at baseline. But over ten years of follow-up, they showed no acceleration in bone density loss at any site [Targownik et al., American Journal of Gastroenterology, 2012].
Lower to start with, but not declining faster. That pattern is what you’d expect if PPI users were simply a group with poorer bone health to begin with — older, less mobile, more comorbidities, more medications — rather than a group whose bones are being damaged by a drug.
The Women’s Health Initiative found much the same. Following 161,806 postmenopausal women for nearly eight years, current PPI use showed a hazard ratio of exactly 1.00 for hip fracture — no association whatsoever. There were modest increases for spine fractures (1.47), wrist or forearm (1.26) and total fractures (1.25). Bone density didn’t differ between users and non-users at baseline, and three-year change was marginal at the hip and absent elsewhere [Gray et al., Archives of Internal Medicine, 2010].
And the randomized evidence agrees. In COMPASS, 17,598 people on pantoprazole or placebo for three years showed no significant difference in fractures [Moayyedi et al., Gastroenterology, 2019].
So should you worry?
My honest read: the bone concern is the weakest of the PPI safety signals. Weaker than the kidney question, and probably weaker than the infection one.
The reasoning isn’t that the fracture studies are wrong — several are large and well conducted, and they consistently find something. It’s that the something they find doesn’t behave like drug-induced bone loss. Bone density doesn’t fall faster. A different drug class shows the same pattern. The risk appears only in people already vulnerable. And risk disappears on stopping, faster than bone could plausibly recover.
All of that points toward the people rather than the pills. There may be a small real effect layered in — possibly through falls rather than bone strength, since some of the confounders here also affect balance and frailty. But “PPIs cause osteoporosis” isn’t supported by the evidence.
Who should still pay attention
Two groups, and they’re worth naming precisely because the general reassurance doesn’t fully cover them.
People already at risk of osteoporosis. The fracture signal concentrated in exactly this group. If you’re postmenopausal, have a family history, have taken long-term steroids, are underweight, smoke, or have had a fragility fracture, your bone health deserves attention regardless of your PPI. Get it assessed on its own terms. Menopause and acid reflux is a common combination, so this overlap catches a lot of people.
Anyone on a PPI who hasn’t had it reviewed. Which brings me to the point that actually matters more than any of the above.
The question underneath all of this
If you have silent reflux, there’s a fair chance your PPI isn’t doing much for you. Acid suppression is genuinely effective for erosive esophagitis and heartburn, but the trials in laryngopharyngeal reflux are disappointing, and the reason is structural: lowering acid production doesn’t stop reflux happening. Pepsin still reaches your throat and reactivates whenever something acidic passes over it. I’ve set the argument out fully in why PPIs don’t work for LPR.
So when someone asks me whether their PPI will damage their bones, my answer is usually: probably not, but why are you still taking it?
That’s not a rhetorical dismissal. It’s the more useful question. A drug with a small uncertain risk and a clear benefit is a good deal. A drug with a small uncertain risk and no measurable benefit isn’t. And the second describes a great many long-term PPI prescriptions for throat symptoms.
The alternative isn’t doing nothing. It’s targeting the reflux itself — the timing, the pH of what you’re eating and drinking, the night-time routine — which is what the Wipeout Diet Plan sets out to do, and what tends to make a PPI genuinely unnecessary rather than merely unhelpful.
Practical bone-health steps if you’re on long-term acid suppression
- Take calcium citrate rather than carbonate if you supplement. Citrate doesn’t need stomach acid to dissolve, so it sidesteps the absorption issue entirely.
- Check vitamin D. Deficiency is common, matters far more for bone than PPIs do, and is easily corrected. Vitamins and acid reflux covers what’s worth taking.
- Get magnesium checked if you’ve been on a PPI for years, since depletion is well documented and relevant to bone metabolism.
- Do weight-bearing exercise. The single most effective thing on this list for bone density, and it’s free.
- Ask for a DEXA scan if you have other risk factors. Actual measurement beats speculation.
If you’d rather not be on the drug at all, don’t stop suddenly — rebound acid hypersecretion will convince you that you needed it. Getting off PPIs and acid rebound covers the taper, and alginate rafts are the most useful cover during the transition because they work mechanically rather than by suppressing acid.
Conclusion
You can put this one fairly far down your list of concerns. The fracture association is real in the data but doesn’t behave like a drug effect — bone density doesn’t decline faster on PPIs, a different drug class shows the same association, the excess risk sits entirely in people already vulnerable, and the randomized trial found nothing. If you’re at risk of osteoporosis, address that directly; it’s worth doing whether or not you ever take another omeprazole.
The more valuable question is whether the drug is earning its place. For silent reflux, often it isn’t — and the answer to that isn’t a different tablet, it’s dealing with what’s driving the reflux in the first place. That’s what the Wipeout Diet Plan does. It’s the full protocol: which foods and drinks reactivate pepsin in your throat and the pH thresholds that decide it, meal timing, the night-time routine, and a structured programme rather than a list of things to avoid. It was designed first around LPR — the throat-based form where acid suppression disappoints most — but because it works on the same underlying mechanisms it’s just as effective for GERD and ordinary heartburn. It’s also what makes coming off a PPI achievable rather than miserable.
For a lighter start, the Wipeout Food Reference Guide is the essential companion — every food and drink that’s safe for acid reflux and LPR with its pH value, so you can check anything in seconds. The Diet Plan is the programme itself; the guide is what sits beside it.
One broader lesson worth carrying away: an association in observational data is a question, not an answer. The bone story has been running for twenty years, and the studies designed to test the actual mechanism kept coming back empty. That’s worth remembering the next time a headline tells you a common medication causes something.
Frequently Asked Questions
Do PPIs cause osteoporosis?
The evidence doesn’t support it. PPI users have somewhat lower bone density on average, but studies following them for up to ten years found no faster bone loss than non-users — which suggests the lower density reflects who takes these drugs rather than what the drugs do.
Should I take calcium if I’m on omeprazole?
If you need calcium supplementation for other reasons, use calcium citrate rather than calcium carbonate. Citrate doesn’t require stomach acid to be absorbed, so acid suppression doesn’t interfere with it. If your dietary calcium is adequate, supplements aren’t automatically necessary.
How long before fracture risk goes up?
In the studies that found an association, it appeared after roughly a year and strengthened with continued use. But given that the same studies found no accelerated bone loss, treat those timelines as descriptions of a statistical pattern rather than a countdown.
Is this worse for postmenopausal women?
The Women’s Health Initiative — the largest study specifically in postmenopausal women — found no hip fracture association at all and only modest increases at other sites, with essentially no bone density difference. Bone health matters a great deal after menopause; the PPI contribution to it looks small.
Are H2 blockers better for bones?
Not clearly. They showed a similar fracture association in the studies that examined both, which is itself part of the reason to doubt that acid suppression is the culprit. If you’re weighing the two, decide on other grounds.
Will a DEXA scan tell me if my PPI is affecting me?
It’ll tell you your bone density, which is genuinely worth knowing if you have risk factors. It won’t tell you what caused any low reading, since a single measurement can’t separate drug effects from age, genetics, activity level and everything else. Useful information, just not an answer to that particular question.
I have osteoporosis and reflux. What now?
Treat the osteoporosis properly — that’s the priority, and it’s manageable. For the reflux, this is a good reason to ask whether long-term acid suppression is the right approach for you or whether the underlying reflux can be addressed directly. Worth raising with both doctors, and worth noting that bisphosphonates for osteoporosis can themselves irritate the esophagus, so the two conditions interact in more than one direction.
Research & References
- [Yang et al., JAMA, 2006] — Nested case-control study of 13,556 hip fracture cases and 135,386 controls found more than a year of PPI therapy associated with hip fracture (odds ratio 1.44), rising to 2.65 with long-term high-dose use, with risk increasing by duration of therapy.
- [Corley et al., Gastroenterology, 2010] — Case-control study of 33,752 hip fracture cases found PPI use associated with fracture (odds ratio 1.30), but excess risk was present only among people with at least one other fracture risk factor, and H2 blockers showed a similar association.
- [Targownik et al., American Journal of Gastroenterology, 2012] — Canadian population study measuring bone mineral density in 8,340 people at baseline, five and ten years found PPI users had lower baseline density but no acceleration of bone density loss at any site over ten years.
- [Gray et al., Archives of Internal Medicine, 2010] — Prospective analysis of 161,806 postmenopausal women in the Women’s Health Initiative found no association between PPI use and hip fracture (hazard ratio 1.00), with modest associations for spine, wrist and total fractures and minimal bone density difference.
- [Moayyedi et al., Gastroenterology, 2019] — Randomized double-blind trial of 17,598 participants on pantoprazole or placebo for a median of three years found no statistically significant difference in fractures or other safety outcomes except enteric infections.
David Gray
12 years living with LPR · Consultant & researcher
I've lived with LPR for twelve years — the misdiagnoses, the PPI courses that did nothing, the slow work of figuring out what actually helps. Wipeout Reflux is where I translate the research into plain terms for people stuck in the same place. Every claim here is sourced to peer-reviewed work, and I consult one-to-one with LPR sufferers.